Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Study Evaluating the Impact of a Painkiller Product on Quality-of-Life and Daily Functioning

16. November 2026 aktualisiert von: HALEON

A Multi-country, Retrospective, Real World Observational Study Evaluating the Impact of an Analgesic Product on Quality-of-Life and Daily Functioning

The aim of this study is to generate real-world, consumer reported evidence on the perceived impact of headache relief with Panadol/Dolex on Quality of Life (QoL) and daily functioning.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This is a multi-country, real-world, observational, cross-sectional survey study. The target population for this survey study comprises individuals who have used Panadol/Dolex for the relief of more than or equal to (>=)1 headache episode in the past 1 month. Eligible participants will be directed to complete an online survey comprising of a series of questions designed to gather data relevant to the research objectives. The study population will be comprised of approximately 2,100 participants across Australia, Malaysia, Colombia, and Kenya.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

2100

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Marina Centre
      • Singapore, Marina Centre, Singapur
        • Virtual site

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Residents of Australia, Malaysia, Colombia, Kenya who have experienced acute primary headaches that occur 1 to 14 days a month on average in the past 1 month and have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.

Beschreibung

Inclusion Criteria:

  • Residents of Australia, Malaysia, Colombia, Kenya.
  • Have experienced acute primary headaches that occur 1 to 14 days a month on average in the past 1 month.
  • Have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.
  • Self-reported healthy individuals.
  • Able to provide informed consent.
  • The specific Panadol/Dolex variant for each country as applicable.

Exclusion Criteria:

  • Participants who experience headaches that occur 15 or more days per month.
  • Participants with migraine.
  • Participants who use any headache medication, pain relief product or alternative remedy (herbal products, supplements, CBD [cannabidiol]- containing pain remedies) concurrently with Panadol/Dolex for the recalled headache episode in the past 1 month.
  • Participants diagnosed by a healthcare professional with chronic pain conditions (fibromyalgia, neuropathic pain, cancer, lupus, multiple sclerosis) who were experiencing symptoms or receiving treatment for the condition at the time of reference headache episode when Panadol/Dolex was used.
  • Breastfeeding or Pregnant at the time of reference headache episode during which Panadol/Dolex was used.
  • Participants affiliated with Sponsor or Contract Research Organization (CRO).

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: CROSS_SECTIONAL

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Panadol/Dolex Tablet

Participants who have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.

Paracetamol 500 milligram (mg) taken orally.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Pain Intensity Before Using Panadol/Dolex
Zeitfenster: Within the past 1 month from time of participation

Thinking about most recent headache episode, participants will be asked to rate the pain intensity experienced before using Panadol/Dolex on a scale 0 to 10, where 0= No pain and 10= Worst possible pain. Lower score indicates better outcome.

Within the past 1 month from time of participation
Perceived Relief From Panadol/Dolex Use
Zeitfenster: Within the past 1 month from time of participation

Thinking about the headache episode, participants will describe the first sign of symptom relief they perceived after taking Panadol/Dolex.

Within the past 1 month from time of participation
QoL Assessment After Using Panadol/Dolex Post Headache Episode
Zeitfenster: Within the past 1 month from time of participation

Thinking about most recent headache episode, participants will be asked to respond to 10 questions related to aspects of daily life when they used Panadol/Dolex after headache episode. The response will be scored using a 5-point scale, where 1= Not at all, and 5= Very Much. Lower score indicates better quality of life.

Within the past 1 month from time of participation

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Frequency of Panadol/Dolex Use
Zeitfenster: Within the past 1 month from time of participation

Thinking about the recent headache episode, participants will be asked to mention the frequency of product use from 1 time a day to 4 times a day.

Within the past 1 month from time of participation
Timepoint of Panadol/Dolex Use
Zeitfenster: Within the past 1 month from time of participation

Participants will answer a single question related to timepoint of product use- 'Thinking about the same headache episode which you used Panadol for relief in the past one month, what did you first do to relieve the pain?' Participants will choose one of the given options.

Within the past 1 month from time of participation
Product Satisfaction
Zeitfenster: Within the past 1 month from time of participation

Thinking about the experience of using Panadol, participants will rate their overall satisfaction on a scale 1 to 5, where 1= Absolutely dissatisfied and 5= Completely satisfied.

Within the past 1 month from time of participation
Headache Management Behaviors
Zeitfenster: Within the past 1 month from time of participation

Participants will answer a single question related to headache management approaches they used before- 'Thinking about similar headaches you experienced before this episode, what did you do to relieve your headache in the past?' Participants will select one or more descriptive options provided.

Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Trust in The Product
Zeitfenster: Within the past 1 month from time of participation

Participants will answer a single question related to trust in the product- 'How much do you trust the product to provide fast headache pain relief?' Participants will choose one of the given options.

Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Value For Money
Zeitfenster: Within the past 1 month from time of participation

Thinking about experience of using the product, participants will be asked to rate the product's value for money on a scale 1 to 5, where 1= Poor value for money and 5= Excellent value for money.

Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Intention to Use Again
Zeitfenster: Within the past 1 month from time of participation

Participants will answer a single question related to continued purchase- 'How likely would you choose Panadol again for your next headache episode?'. Participants will choose one of the given options.

Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Intention to Recommend Other Consumers
Zeitfenster: Within the past 1 month from time of participation

Participants will answer a single question related to likelihood to recommend others- How likely would you recommend Panadol to other consumers experiencing headache pain? Participants will choose one of the given options.

Within the past 1 month from time of participation

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Dezember 2026

Primärer Abschluss (Geschätzt)

1. Januar 2027

Studienabschluss (Geschätzt)

1. Januar 2027

Studienanmeldedaten

Zuerst eingereicht

16. Oktober 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

26. Oktober 2026

Zuerst gepostet (Tatsächlich)

2. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

17. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

16. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com

IPD-Sharing-Zeitrahmen

IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

IPD-Sharing-Zugriffskriterien

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren